| 代利霞,涂小琼,蔡冰冰.达沙替尼治疗不同临床分期慢性粒细胞白血病患者的临床研究[J].肿瘤学杂志,2018,24(10):997-1001. |
| 达沙替尼治疗不同临床分期慢性粒细胞白血病患者的临床研究 |
| Clinical Efficacy of Dasatinib in the Treatment of Different Stages of Chronic Myelogenous Leukemia |
| 投稿时间：2017-06-12 |
| DOI：10.11735/j.issn.1671-170X.2018.10.B012 |
|
 |
| 中文关键词: 慢性粒细胞白血病 达沙替尼 慢性期 加速期 急变期 临床疗效 |
| 英文关键词:chronic myeloid leukemia dasatinib chronic phase accelerated phase blast crisis clinical efficacy |
| 基金项目: |
|
| 摘要点击次数: 1596 |
| 全文下载次数: 384 |
| 中文摘要: |
| 摘 要：［目的］ 探讨达沙替尼治疗不同临床分期慢性粒细胞白血病（CML）患者的临床疗效。［方法］ 收集接受达沙替尼治疗的CML患者84例，其中慢性期（CP组）51例，加速期（AP组）18例，急变期（BP组）15例。比较3组的缓解情况、药物相关不良反应及生存情况。［结果］ CP组的完全血液学缓解（CHR）率、完全细胞遗传学反应（CCR）缓解率及主要分子生物学缓解（MMR）率分别为92.16%、86.27%、78.43%，显著高于AP组的72.22%、61.11%、44.44%和BP组的66.67%、53.33%、40.00%（P均<0.05）；CP组的中位总生存（OS）时间、中位无复发生存（RFS）时间均显著长于AP组和BP组（P<0.05）；CP组随访期内死亡率为1.96%，显著低于AP组的22.22%和BP组的26.67%（P<0.05）；CP组的Ⅲ~Ⅳ级血液学不良反应发生率为13.73%，显著低于AP组的38.89%和BP组的46.67%（P<0.05）。［结论］ 达沙替尼治疗CML的疗效显著且安全性好，是治疗慢性期CML的优先治疗选择。 |
| 英文摘要: |
| Abstract：［Objective］ To evaluate the clinical efficacy of dasatinib in the treatment of different stages of chronic myelogenous leukemia(CML). ［Methods］ Totally 84 patients with CML were enrolled，including 51 in the chronic phase(CP group)，18 in the accelerated phase(AP group) and 15 in the blast phase(BP group).The remission，drug-related adverse reactions and survival condition of the three groups were compared. ［Results］ The complete hematologic response(CHR)，complete cytogenetic response(CCR) and major molecular biology remission(MMR) ratesofthe CP group were 92.16%，86.27% and 78.43%，respectively，significantly higher than those of the AP group(72.22%，61.11% and 44.44%，respectively；P<0.05)and theBP group(66.67%，53.33% and 40.00%，respectively；P<0.05).The median overall survival(OS) time and median recurrence-free survival(RFS) time of the CP group were both significantly longer than those of the AP group and the BP group(P<0.05).The death rate in the follow-up period of the CP group(1.96%)was significantly lower than thoseof the AP group(22.22%) and the BP group(26.67%)(P<0.05). The incidence rate of grade Ⅲ/Ⅳhematologic adverse events was 13.73% in the CP group，significantly lower than that of the AP group(38.89%) and the BP group(46.67%)(P<0.05).［Conclusion］ Dasatinib is an effective and safe alternative for treating chronic CML. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |